Urol. praxi. 2016;17(3):111-116 | DOI: 10.36290/uro.2016.029
Systemic radiotherapy for prostate cancer with bone metastases
- Urologická klinika VFN a 1. LF UK v Praze
Castration-resistant prostate cancer is a complex disease, treatment requires a multidisciplinary approach and use of various
modalities, ideally in their combination. Symptomatic bone metastases can be also effectively managed by administration of
systemic beta emitters (strontium-89 and samarium-153) or localized external beam radiotherapy. Most recently, an alpha emitter
radium-223 has been introduced with a positive impact on increased overall survival of patients with bone metastases. Safety
profile of radium-223 is very favorable with a minimal risk of serious hematologic complications. Six intravenous injections are
administered on an outpatient basis with a positive effect on the quality of life and with minimal restrictions with regard to the
patient’s and his family’s daily life.
Keywords: castration-resistant prostate cancer, systemic radiotherapy, radium-223
Published: August 1, 2016 Show citation
References
- Lien LM, Tvedt B, Heinrich D. Treatment of castration-resistant prostate cancer and bone metastases with radium-223 dichloride. Int J Urol Nurs. 2015; 9(1): 3-13.
Go to original source... 
Go to PubMed... - N?rgaard M, Jensen A?, Jacobsen JB, et al. Skeletal related events, bone metastasis and survival of prostate cancer: a population based cohort study in Denmark (1999 to 2007). J Urol. 2010; 184(1): 162-167. Go to original source... Go to PubMed...
- Heidenreich A, Bastian PJ, Bellmunt J, et al. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol. 2014; 65(2): 467-479. Go to original source... Go to PubMed...
- Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013; 369(3): 213-223. Go to original source...
- Montebello JF, Hartson-Eaton M. The palliation of osseous metastasis with 32P or 89Sr compared with external beam and hemibody irradiation: a historical perspective. Cancer Invest 1989; 7: 139-160. Go to original source...
- Goyal J, Antonarakis ES. Bone-targeting radiopharmaceuticals for the treatment of prostate cancer with bone metastases. Cancer Lett. 2012; 323(2): 135-146. Go to original source... Go to PubMed...
- Autio KA, Pandit-Taskar N, Carrasquillo JA, et al. Repetitively dosed docetaxel and ???samarium-EDTMP as an antitumor strategy for metastatic castration-resistant prostate cancer. Cancer. 2013; 119(17): 3186-3194. Go to original source...
- Bors? E, Boni G, Pastina I, et al. Safety and antitumor efficacy of (153)Sm-EDTMP and docetaxel administered sequentially to patients with metastatic castration-resistant prostate cancer. Nucl Med Commun. 2014; 35(1): 88-94. Go to original source... Go to PubMed...
- Quadramet INJ SOL 2-4.0 GB. Souhrn údajů o přípravku [online] [cit.2016-03-26]. Dostupný na WWW: http://www.ema.europa.eu/docs/cs_CZ/document_library/EPAR_-_Product_Information/human/000150/WC500041751.pdf.
- Yeku O, Slovin SF. Metabolism and pharmacokinetics of radium-223 in prostate cancer. Expert Opin Drug Metab Toxicol. 2015; 11(5): 843-849. Go to original source...
- Nilsson S, Franzén L, Parker C, et al. Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study. Lancet Oncol 2007; 8: 587-594. Go to original source...
- Parker C, Vogelzang NJ, Sartor O, et al. 3-Year Safety Follow-up of Radium-223 Dichloride in Patients With Castration-Resistant Prostate Cancer and Symptomatic Bone Metastases From ALSYMPCA. J Clin Oncol 33, 2015 (suppl 7; abstr 195). Go to original source...
- Vogelzang NJ, Fernandez DC, Morris MJ, et al. Radium-223 dichloride (Ra-223) in U.S. expanded access program (EAP). J Clin Oncol 33, 2015 (suppl 7; abstr 247). Go to original source...
- Smith MR, Parker C, Tombal BF, et al. ERA 223: A phase 3 trial of radium-223 dichloride (Ra-223) in combination with abiraterone acetate (abiraterone) and prednisone in the treatment of asymptomatic or mildly symptomatic chemotherapy-na?ve patients (pts) with bone predominant metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol 33, 2015 (suppl; abstr TPS5082). Go to original source...
- Sartor AO, Heinrich D, Mariados N, et al. Radium-223 (Ra-223) re-treatment (Re-tx): First experience from an international, multicenter, prospective study in patients (Pts) with castration-resistant prostate cancer and bone metastases (mCRPC). J Clin Oncol 34, 2016 (suppl 2S; abstr 197). Go to original source...
- Shore ND, Tutrone RF, Mariados NF. Open-label phase II study evaluating the efficacy of concurrent administration of radium Ra 223 dichloride (Ra-223) and abiraterone acetate (AA) in men with castration-resistant prostate cancer (CRPC) patients with symptomatic bone metastases. J Clin Oncol 34, 2016 (suppl 2S; abstr 177). Go to original source...
- Kubinyi J. Bezpečnost při kontaktu s pacienty po aplikaci 223-Radia. Vklad do Českého vydání THE LANCET Oncology/ročník 14/ číslo 4 / listopad 2015. Go to PubMed...